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Pevere Disease Expression of Cardiac
roponin C and T Mutations in
atients With Idiopathic Dilated Cardiomyopathy
ens Mogensen, MD, PHD,* Ross T. Murphy, MD,* Tony Shaw, PHD,* Ajay Bahl, MD,*
harles Redwood, PHD,‡ Hugh Watkins, MD, PHD,‡ Margaret Burke, MD,† Perry M. Elliott, MD,*
illiam J. McKenna, MD*
ondon, Middlesex, and Oxford, United Kingdom
OBJECTIVES We performed genetic investigations of cardiac troponin T (TNNT2) and troponin C
(TNNC1) in 235 consecutive patients with idiopathic dilated cardiomyopathy (DCM) to
evaluate prevalence of mutations and associated disease expression in affected families.
BACKGROUND Recently, mutations in sarcomeric genes have been reported in DCM. However, the
prevalence, penetrance, and clinical significance of sarcomere gene mutations in large
consecutive cohorts of DCM patients are poorly defined.
METHODS Mutation detection was performed by fluorescent SSCP/DHPLC analysis and direct
sequencing. The functional effects of mutations on interactions within the troponin complex
were assessed by a two-hybrid luciferase assay.
RESULTS A total of 43% (102 of 235) of the study cohort had familial DCM. One TNNC1 and four
TNNT2 (three novel) mutations were identified in one and four families, respectively. The
prevalence of TNNC1/TNNT2 mutations in familial DCM was 5% with a penetrance of
100%. A total of 21 mutation carriers were identified; 6 underwent cardiac transplantation, 5
died of heart failure, and 4 died suddenly at a mean age of 29 years, while 6 remained stable
on medication. Functional studies showed significant impairment of mutated troponin
interaction compared with wild-type control, indicating an altered regulation of myocardial
contractility.
CONCLUSIONS Cardiac troponin C was identified as a novel DCM gene. The disease expression associated
with TNNC1 and TNNT2 mutations was severe with complete penetrance. The data suggest
that mutation analysis of the troponin complex in DCM patients may prove valuable in early
identification of individuals with an adverse prognosis and a high risk of premature death.
This may lead to improved management and survival. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.0272033–40) © 2004 by the American College of Cardiology Foundation
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tdiopathic dilated cardiomyopathy (DCM) is the most
ommon cause of heart failure and cardiac transplantation in
he young. The condition is characterized by unexplained
eft ventricle dilation, impaired systolic function, and non-
pecific histologic abnormalities dominated by myocardial
brosis. Patients may experience severe disease complica-
ions including arrhythmia, thromboembolic events, and
See page 2041
udden death. Recent studies have suggested familial disease
n 30% to 50% of cases. Autosomal dominant transmission
s most frequent followed by recessive, X-linked, and mito-
hondrial inheritance. Most affected families present with a
pure” cardiac phenotype while syndromic features are less
requent. Disease-causing mutations have been reported in
enes encoding cytoskeletal and nuclear envelope proteins
nd, more recently, in sarcomeric contractile protein genes
From the *Department of Cardiological Sciences, St. George’s Hospital Medical
chool, London, United Kingdom; †Harefield Hospital, Middlesex, United Kingdom;
nd ‡John Radcliffe Hospital, Oxford, United Kingdom. Supported by the British Heart
oundation.f
Manuscript received March 22, 2004; revised manuscript received July 29, 2004,
ccepted August 3, 2004.1–3). At present, 10 different mutations in 12 families with
utosomal dominant DCM have been identified in the
arcomeric genes for alpha-cardiac actin (ACTC), alpha-
ropomyosin (TPM1), cardiac troponin T (TNNT2), beta-
yosin heavy chain (MYH7), and titin (TTN) (4–11). In
ddition, we recently reported the first recessive mutation in
ardiac troponin I (TNNI3) in a small DCM family with
arly and severe disease expression (10).
The fact that DCM mutations have been identified in
NNT2 and TNNI3 led us to investigate whether muta-
ions in the remaining part of the troponin complex (cardiac
roponin C [TNNC1]) were present in DCM. This study
xamines the relationship between genotype and clinical
henotype in families with mutations in TNNC1 and
NNT2 identified by mutation analysis of 235 consecutive
CM patients and their relatives. In addition, we report the
ffect of TNNC1 and TNNT2 mutations identified on
nter-troponin interactions by the use of a qualitative mam-
alian two-hybrid luciferase assay.
ETHODS
linical investigations. The local research ethics commit-
ee approved the study, and informed consent was obtained
rom all participants.
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Troponin C and T Mutations in DCM November 16, 2004:2033–40The study cohort consisted of 235 consecutive and
nrelated DCM probands who were evaluated in a dedi-
ated cardiomyopathy clinic from 1995 to 2002. Relatives of
CM probands in whom a TNNT2 or TNNC1 mutation
as identified were invited for clinical assessment. All
articipants underwent physical examination, 12-lead elec-
rocardiogram, transthoracic two-dimensional echocardiog-
aphy, and Doppler studies. Cardiac catheterization was
erformed in patients aged 40 years, and in those indi-
iduals with symptoms of ischemic heart disease or exercise-
nduced ST-segment changes consistent with myocardial
schemia. Familial disease was defined where one or more
elatives had DCM identified by clinical investigation or
ad a family history of unexplained premature cardiac death
40 years.
chocardiography. Standard measurements of left ventric-
lar end-diastolic dimension (LVEDD) and left ventricular
nd-systolic dimension (LVESD) were performed, and
ractional shortening was calculated as (LVEDD 
VESD/LVEDD)  100. Dimensions were corrected for
igure 1. Pedigree drawings of dilated cardiomyopathy (DCM) families a
entricular wall thickness by echocardiography, and no patients had atriov
embers; circles  female family members; symbols with slash  dec
Abbreviations and Acronyms
DCM  dilated cardiomyopathy
DHPLC  denaturing high performance liquid
chromatography
F-SSCP  fluorescent SSCP
LVEDD  left ventricular end-diastolic dimension
LVESD  left ventricular end-systolic dimension
TNNC1  cardiac troponin C
TNNI3  cardiac troponin I
TNNT2  cardiac troponin Tndividuals affected by DCM; half-solid symbols  individual with left ventr
uestion marks  unknown clinical status; plus signs  presence of mutationge and body surface area (BSA) according to the formula of
enry [(LVEDD)(percent predicted)  measured
VEDD/predicted LVEDD  100; predicted LVEDD 
45.3  BSA0.3]  [0.03  age]  7.2 (12).
Dilated cardiomyopathy was diagnosed in accordance
ith World Health Organization diagnostic criteria when
chocardiography identified unexplained left ventricle dila-
ion and impaired contractile performance: left ventricular
nd diastolic diameter 117% predicted for age and body
urface area and a fractional shortening 25%. Relatives of
CM probands were considered to be affected if they had
nexplained left ventricle enlargement 112% of predicted
alue or experienced unexplained heart failure or sudden
ardiac death at 40 years of age (1,13). Patients with
ymptoms or signs of skeletal muscle disease were excluded
rom the study.
utation analysis. Genomic deoxyribonucleic acid was
btained, and protein encoding exons of TNNT2 and
NNC1 were amplified using standard protocols (primer
equences and conditions for polymerase chain reaction
mplification available upon request). Mutation analysis of
NNT2 was performed by fluorescent SSCP (F-SSCP) and
irect sequencing of abnormal conformers. As reported
reviously, the sensitivity of F-SSCP to identify sequence
ariations in TNNT2 was 100% (14); TNNC1 was investi-
ated by denaturing high performance liquid chromatogra-
hy (DHPLC) analysis and abnormal elution profiles sub-
ected to direct sequencing. Initially, 50 patients were
nvestigated for mutations in TNNC1 by direct sequencing
ithout identifying any sequence variations. Subsequent
HPLC analysis of the remaining patients identified one
by cardiac troponin C and T mutations. All individuals had normal left
cluar block or impaired skeletal muscle function. Squares  male family
individuals; open symbols  unaffected individuals; solid symbols ffected
entri
easedicle enlargement; checkered symbols  individuals who died suddenly;
; minus signs  absence of mutation.
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November 16, 2004:2033–40 Troponin C and T Mutations in DCMequence variation indicating a high sensitivity of this
nvestigation as previously reported (14). When a mutation
as identified, a second blood sample from the affected
atient was reanalyzed to confirm the initial finding by
irect sequencing, F-SSCP, or DHPLC analysis.
unctional studies. To delineate the effect of TNNC1 and
NNT2 mutations identified on inter-troponin interac-
ions, we used a qualitative mammalian two-hybrid lucif-
rase assay. The TNNT2 cDNA was cloned into the
BIND plasmid (Promega, Madison, Wisconsin) and the
NNI3 and TNNC1 cDNA were cloned into the pACT
lasmid (Promega). The cloning result was confirmed by
irect sequencing and compared with accession numbers
90780 (TNNI3), AY044273 (TNNT2), and M37984
TNNC1) (15). Mutations identified in TNNT2 (R131W,
205L, K210, D270N, and a recognized polymorphism,
253R) and TNNC1 (G159D) were introduced into
able 1. Clinical Characteristics of DCM Families With TNNC1
ID Age/Gender NYHA
amily A, TNNC1:
ly159Arg
IV-4* 21/M 4
IV-5‡ 36/F 1
IV-7 20/F 2
III-4* 45/F 4
III-1* 52/M 4
IV-2* 22/M 4
III-6 21/F NA
II-1 62/M 3
amily B, TNNT2:
rg131Trp
II-3 23/F 3
II-2 16/M 1
I-2 34/F 3
amily C, TNNT2:
rg205Leu
III-1* 16/F 3
III-2§ 20/F 4
II-2 45/F 2
I-2 24/F 1
amily D, TNNT2:
ys210del
III-3† 25/M 3
III-4* 21/M 4
III-1 35/M 1
II-1 36/M 1
amily E, TNNT2:
sp270Asn
II-1† 38/M 4
III-2 19/M 1
Autopsy of diseased individuals and examination of explanted hearts showed chamb
ntemortem were consistent with DCM; ‡Individual IV-5 was assumed to be a
lectrocardiogram with T-wave inversion in V1–V2 and left-axis deviation; §Died o
DCM dilated cardiomyopathy; FS fractional shortening; HTx cardiac trans
A  not available; NYHA  New York Heart Association.BIND-TNNT2 and pACT-TNNC1, respectively, by tligonucleotide-mediated site-directed mutagenesis.
EK293 cells were cotransfected with equimolar amounts
f pBIND-TNNT2 (wild-type [wt] or mutant), pACT-
NNI3, or pACT-TNNC1 (wild-type or mutant) and the
G5Luc reporter plasmid. After 48 h, cell lysates were
ssayed for Photinus and Renilla luciferase using the Pro-
ega dual-luciferase assay system. Data was normalized
gainst Renilla luciferase activity to account for differences
n transfection efficiency. The values for the interaction
etween wild-type protein troponin T (cTnT), I (cTnI),
nd C (cTnC) were arbitrarily set to 100%. The values for
nteractions between mutant cTnT and cTnC or cTnI were
xpressed relative to this. All experiments were repeated 10
imes. The values for luciferase activity resulting from
nteraction of mutated cTnT–wild-type cTnI and mutated
TnT–wild-type cTnC were compared with luciferase ac-
ivities obtained from interaction of wild-type cTnT–wild-
NNT2 Mutations
Echocardiography
Diagnosis and OutcomeLVEDD FS%
NA NA DCM, HTx age 22
54 37 LVE, current age 37
57 21 DCM, current age 22
NA NA DCM, heart failure death age
45
81 8 DCM, HTx age 52
83 11 DCM, HTx age 22
NA NA Sudden death age 21
NA NA Heart failure death age 62
83 10 DCM, current age 28
NA NA Sudden death age 16
59 15 DCM, heart failure death age
34
68 6 DCM, HTx age 16
NA NA DCM, heart failure death age
20
50 21 DCM, current age 48
NA NA Sudden death age 24
74 14 DCM, heart failure death age
26
NA NA DCM, HTx age 22
49 24 DCM, current age 36
NA NA Sudden death age 36
83 10 DCM, HTx age 38, died age 44
53 21 DCM, current age 21
tion with cardiac weights ranging from 450–540 g; †Histology of biopsies obtained
because she had LV enlargement (115% of predicted value) and an abnormal
failure despite implantation of LV assist device.
LVE left ventricle enlargement; LVEDD left ventricle end-diastolic dimension;or T
er dila
ffected
f heartype cTnI and wild-type cTnT–wild-type cTnC by use of a
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Troponin C and T Mutations in DCM November 16, 2004:2033–40test. The values for luciferase activity were distributed in
ccordance with a normal distribution, and an F-test
howed homogeneous distribution of variances (data not
hown). Likewise, values for luciferase activity resulting
rom interaction of mutated cTnC–wild-type cTnI and
utated cTnC–wild-type cTnT were compared with lucif-
rase activities obtained from interaction of wild-type
TnC–wild-type cTnI and wild-type cTnC–wild-type
TnT by use of same t test and conditions. Control
xperiments consisting of cotransfections of pBIND,
G5Luc, and pACT-TNNC1 or pACT-TNNI3 (wild type
nd mutants) as well as pBIND-TNNT2 (wild-type and
utants), pG5Luc, and pACT were performed without
bserving any interaction (data not shown).
ESULTS
haracteristics of the study cohort. A total of 43% (102
f 235) of the study cohort had one or more relatives with
CM identified by clinical investigation or a family history
f premature cardiac death at 40 years of age. A total of
5% of these families (87 of 102) exhibited an autosomal
ominant mode of inheritance, whereas the remaining 15%
15 of 102) transmitted the condition consistent with
utosomal recessive inheritance, although autosomal domi-
ant inheritance with incomplete penetrance could not be
xcluded. Inheritance patterns suggestive of maternal or
-linked inheritance were not observed.
linical characteristics of genotype-positive families.
utation analysis of TNNC1 in family A identified a
issense mutation that was predicted to result in a G159D
mino acid substitution (Fig. 1, Table 1). The mutation was
resent in all affected individuals and absent in 200 chro-
osomes from ethnically matched control individuals. The
roband, IV-4, had a sudden onset of heart failure symp-
oms at the age of 21 years. His cardiac function deterio-
ated rapidly, and he underwent cardiac transplantation two
onths after initial presentation. Two additional individu-
able 2. Conservation of Cardiac Troponin T (cTnT) Amino Ac
rotein Encoding Exon Exon 10
Amino Acid Position 131 2
Human cTnT E N R K K T E
amily B . . W . . . .
amily C . . . . . . .
amily D . . . . . . .
amily E . . . . . . .
ovine cTnT . . . . . . .
at cTnT . . . . . . .
ouse cTnT . . . . . . .
abbit cTnT . . . . . . .
hicken cTnT . Q . . . . .
ebrafish cTnT . . . . . . .
vine cTnT . . . . . . .
scidian cTnT . S . . Q . .
eriod indicates amino acid identity. Accession numbers for rat, mouse, chicken, rabbit
25345, AF175558, P50751, NP_690853, D50867, respectively (15).ls, III-1 and IV-2, received cardiac transplants at the age of T2 and 22 years; III-1 had been evaluated at the age of 50
ears at the time of his son’s transplant of which he had
ormal systolic function. However, two years later he
eveloped dyspnea and edema of the lower extremities due
o heart failure and required transplantation two months
fter onset of symptoms. The mother of the proband, III-4,
ho was an obligate mutation carrier, died at the age of 45
ears awaiting cardiac transplant, while II-1 died of heart
ailure (age 62 years), after eight months of medical treat-
ent. Postmortem examination showed dilation of all
ardiac chambers, and a heart weight of 540 g; III-6
xperienced unexplained sudden death at the age of 21
ears; IV-7 was diagnosed with DCM at the age of 17 years
nd has been stabilized on angiotensin-converting enzyme
nhibitors for the past year, whereas IV-5, age 36 years, has
eft ventricle enlargement on echocardiography and electro-
ardiographic abnormalities including T-wave inversion in
1 to V2 and left-axis deviation.
Mutation analysis of TNNT2 identified four different
utations in four families of which three were novel (family
, R131W; family C, R205L; family E, D270N) and one
as previously been reported (family D, K210) (Fig. 1,
able 1) (7,9). The mutations identified segregated with the
isease in each family and were absent in 200 chromosomes
rom ethnically matched control individuals and 1,520
hromosomes from patients with hypertrophic cardiomyop-
thy. The disease expression in the four families with
NNT2 mutations was similar to family A in severity.
hree individuals (family C, III-1; family D, III-4; family
, II-1) received cardiac transplants at the age of 16, 22, and
8 years, respectively. Three individuals died of heart failure
family B, I-2; family C, III-2; family D, III-3), three died
uddenly (family B, II-2; family C, I-2; family D, II-1),
hereas four have remained stable on conventional heart
ailure therapy.
In this study, 21 individuals were identified with muta-
ions in TNNC1 (n  8) and TNNT2 (n  13) (Fig. 1,
esidues Affected by Mutations
Exon 13 Exon 15
210 270
E K K K K I L I N D N Q
. . . . . . . . . . . .
. . . . . . . . . . . .
. . . . del . . . . . . .
. . . . . . . . . N . .
. . . . . . . . . . . .
. . . . . . . . . . . .
. . . . . . . . . . . .
. . . . . . . . . . . .
. . . . . . . V S . H .
. . . . . . F V S . H .
. . . . . . . V . . . .
. . . . . L . V N E Y M
e, ovine, zebrafish, and ascidin troponin T are: NM_012676, NM_011619, M10013,id R
05
R
.
L
.
.
.
.
.
.
.
.
.
.able 1). Five died of heart failure, and six received a cardiac
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November 16, 2004:2033–40 Troponin C and T Mutations in DCMransplant (average age: 33 years, range: 20 to 62 years) 6
onths after initial diagnosis (range: 2 to 8 months). Four
xperienced sudden unexplained death (average age: 24
ears, range: 16 to 36 years). In total, 71% (15 of 21)
xperienced premature cardiac death or underwent cardiac
ransplantation. Six mutation carriers are currently alive (five
ith DCM and one with left ventricular enlargement) and
ave remained stable (New York Heart Association func-
ional class I) on heart failure therapy during an average
bservation period of 30 months (range: 20 to 150 months)
Table 1). The average number of premature cardiac deaths
er family with troponin disease (2.6 deaths/family) was
ignificantly higher compared with the death ratio observed
n the remaining families of the cohort with hereditary
CM (0.7 deaths/family) (p  0.001, Fisher exact test).
he penetrance of mutations in both TNNC1 and TNNT2
as 100%.
istology. Myocardial tissue from eight patients was avail-
ble for histologic evaluation (two biopsies obtained ante-
ortem [D: III-3; E: II-1], two hearts from autopsies [A:
II-4; C: II-2], and four explanted hearts [A: III-1, IV-2,
V-4; C: III-1]). All specimens showed varying degrees of
onspecific abnormalities including myocyte hypertrophy,
ncreased interstitial fibrosis, and endocardial thickening
ith smooth muscle cells characteristic of DCM (16).
here was no significant myocyte disarray characteristic of
ypertrophic cardiomyopathy or features suggesting storage
isease in any of the specimens evaluated (17,18).
able 3. Conservation of Cardiac Troponin C (cTnC) Amino
cids Affected by Mutation
Protein Encoding Exon
mino acid position 159
uman cTnC M K G V E
amily A . . D . .
ovine cTnC . . . . .
ouse cTnC . . . . .
hicken cTnC . . . . .
uail cTnC . . . . .
enopus cTnC . . . . .
ebrafish cTnC . . . . .
ufferfish cTnC . . . . .
amprey cTnC . . . . D
ccession numbers for mouse, bovine, chicken, quail, xenopus, zebrafish, pufferfish,
nd lamprey troponin C are: M29793, P02590, D13037, M29722, AB003080,
F434188, AF434190, AB00856, respectively (15).
igure 2. Schematic representation of the human cardiac troponin T gene s
18–22). The stars indicate mutations identified in patients with dilated cardiomy
, and D270N in family E.unctional studies of troponin C and T mutations. The
utations identified were all localized in conserved and
unctionally important domains of the proteins involved in
he interaction with other troponin subunits and/or tropo-
yosin (Tables 2 and 3, Fig. 2) (19–23). The effect of the
utations on cTnI, cTnT, and cTnC protein interactions
as qualitatively assessed by a mammalian two-hybrid assay
Fig. 3). There was a significant impairment of mutated
TnTR131W, R205L, K210, D270N–cTnIwt and cTnTR131W,
205L, K210, D270N–cTnCwt protein interactions compared
ith wild-type controls (t test: p  0.001). Likewise, a
ignificant impairment of mutated cTnCG159D–cTnTwt
rotein interaction was observed, whereas the interaction
etween cTnCG159D–cTnIwt was significantly enhanced (p
alues for both experiments 0.001). No significant change
as observed after similar inter-troponin protein interaction
tudies of a recognized cTnT amino acid polymorphism
K253R), which appeared with a frequency of 2.3% in
ontrols (Fig. 3).
All mutations identified were believed to be disease-
ausing because: 1) they co-segregated with disease in each
f the five families; 2) no sequence variations were identified
n 200 ethnically matched control chromosomes investi-
ated in TNNT2 and TNNC1 or 1,520 chromosomes from
ypertrophic cardiomyopathy patients investigated in
NNT2; 3) the mutations were localized in conserved and
unctionally important regions of the genes; and 4) func-
ional studies of the mutated proteins showed altered
roponin protein-protein interactions.
ISCUSSION
linical and genetic investigations. Cardiac troponin C
as identified as a novel disease gene in DCM. In addition,
our disease-causing mutations were found in TNNT2,
hereas our previous investigation of the same cohort of
atients for autosomal dominant mutations in TNNI3 was
egative (10). The overall frequency of mutations in the
roponin complex in familial DCM was 6% (6 of 102)
ncluding a previously reported recessive TNNI3 mutation
10). The disease expression appeared malignant because
1% (15 of 21) of mutation carriers experienced premature
ardiac death or received a cardiac transplant mostly by the
ourth decade with an average duration of six months from
ng interaction sites with other thin filament sarcomeric contractile proteinshowi
opathy (DCM), R131W in family B, R205L in family C, K210 in family
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Troponin C and T Mutations in DCM November 16, 2004:2033–40iagnosis to event. Recent investigations of TNNT2 in
CM families have identified a K210 deletion in three
nrelated families and an R143W amino acid substitution
n one family (6,7,9). The clinical disease expression in these
amilies was similarly severe, and a significant number of
ffected individuals experienced premature cardiac death/
ransplantation in the second or third decade of life.
owever, the disease expression reported was more variable,
nd healthy mutation carriers without signs and symptoms
f disease were present even at older ages. The design of
revious studies did not allow an estimate of the prevalence
igure 3. Effect of troponin C (cTnCG159D) and troponin T (cTnTR131W
ssessed by a mammalian two-hybrid assay. All mutations impaired cTnT
ild-type protein interaction (cTnTwt, cTnCwt, cTnIwt). A recognized tro
ignificantly compared with wild-type troponin interaction. All experimenf TNNT2 mutations in consecutive DCM patients. btility of genetic investigations. Overall, the clinical ex-
ression of mutations in the troponin complex was associ-
ted with an adverse prognosis in DCM. However, this and
ther studies have reported the clinical findings in patients
iagnosed over decades in which advances in pharmacologic
reatment have substantially improved the prognosis of
atients with heart failure. Although a limited number of
atients with DCM in this study are currently alive with a
elatively short observation period, it is of note that their
ondition appears stable on modern pharmacologic therapy
ith angiotensin-converting enzyme inhibitors and beta-
R205L, cTnTK210, cTnTD270N) mutations on inter-troponin interactions
C and cTnT-cTnI interaction significantly (p  0.001) compared with
T polymorphism (cTnTK253R) did not change inter-troponin interaction
re repeated 10 times. Vertical bars  standard deviation., cTnT
-cTn
poninlockers. The results of previous drug trials of patients with
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November 16, 2004:2033–40 Troponin C and T Mutations in DCMeart failure have indicated a beneficial effect of prophylactic
harmacologic therapy in asymptomatic individuals with
mpaired systolic function (24,25). Therefore, it is reason-
ble to assume that early diagnosis and treatment of asymp-
omatic patients with hereditary DCM may also improve
heir prognosis (26). The many premature cardiac deaths
bserved suggest that regular clinical investigation of rela-
ives at risk of disease development is warranted to ensure
arly diagnosis. Genetic diagnosis would be helpful in
dentifying unaffected mutation carriers who require
ollow-up and would enable termination of clinical screen-
ng of relatives with a normal genotype. In addition,
nowledge of the specific disease gene and mutation present
n a family may allow risk-stratification, although limited
ata are available in relation to sarcomeric gene mutations.
o far, few families have been identified, and only the genes
or ACTC, TPM1, and TNNI3 have been fully investigated
n large cohorts of DCM families with a frequency of
utations that account for 3% of all cases (4,5,10). Most
ther patient populations studied were small in number, and
ur findings reemphasize the importance of designing
enetic studies in larger DCM populations to describe the
revalence of these mutations. The fact that we investigated
atients with a “pure” cardiac phenotype explains that we
id not observe inheritance patterns suggestive of maternal
r X-linked inheritance because these conditions are often
ssociated with symptoms of systemic disease. In maternal
nheritance caused by mithocondrial gene mutations, pa-
ients typically have multiorgan disease including dilated or
ypertrophic cardiomyopathy, neurological symptoms, and
keletal muscle impairment. In X-linked inheritance caused
y dystrophin mutations, the disease expression is most
ommonly associated with both DCM and skeletal muscle
mpairment, although a few patients with a “pure” cardiac
henotype have been reported.
unctional studies. Myocardial contractility is largely reg-
lated by the troponin complex that, in turn, is influenced
y the concentration of intracellular Ca2. The complex is
istributed along the thin filament of the sarcomere and
nteracts with actin and tropomyosin. During systole, Ca2
inds to cTnC and introduces conformational changes of
he troponin complex that attenuate the inhibitory effect of
TnI. This enables the myosin head of the thick filament to
nteract with actin and generate force. The Ca2 concen-
ration also influences cTnC-cTnT interaction which is
mportant for control of sliding velocity between thick and
hin filament (19–23). Interestingly, recent studies have
uggested that cTnT is essential, not only for the structural
ntegrity of the troponin complex, but also for sarcomere
ssembly and cardiac contractility (27).
The amino acid substitution identified in TNNC1
G159D) is localized in a domain of the protein constitu-
ively occupied by Ca2. This may change the affinity for
a2 and, thereby, alter the ability of the troponin complex
o regulate myocardial contractility. Also, mutations iden-
ified in TNNT2 (R131W, R205L, K210, D270N) oc-urred in well-conserved regions essential for interactions
ithin the troponin complex or its interactions with tropo-
yosin or actin (19–23,28,29). The qualitative effect of the
utations on inter-troponin interactions was investigated
sing a mammalian two-hybrid assay, which showed signif-
cant changes for all mutant proteins compared with wild-
ype. A common TNNT2 polymorphism (K253R) served as
negative control in the test system and did not change
nter-troponin interactions. The results indicate that this
ssay may be helpful in providing supporting evidence to
etermine if an amino acid change identified in an affected
ndividual is a disease-causing mutation or more likely to be
polymorphism.
Previous functional studies of one of the DCM mutations
dentified (TNNT2, K210) showed that mutated protein
educed the Ca2 sensitivity of actomyosin ATPase activity,
hich resulted in decreased maximum speed of muscle
ontraction (30,31). Thus, DCM mutations in the troponin
omplex may induce a profound reduction in force genera-
ion leading to impaired systolic function and cardiac
ilation. In addition, it is possible that the myocardium of
utation carriers may be more susceptible to environmental
nfluences such as viruses and toxic agents. It seems likely
hat the heterogeneous clinical appearance in DCM families
ith mutations in the troponin complex is a result of
nterplay between the specific mutation identified, modifier
enes, and non-genetic factors in the environment.
In summary, mutations in the three proteins of the
roponin complex were not uncommon in DCM. The
isease expression was characterized by high penetrance and
evere prognosis. The data suggest that genetic investiga-
ions of the troponin complex may help to identify a subset
f DCM families at high risk of rapid disease development.
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